CATALOGO DEI PRODOTTI DELLA RICERCA

Ciccarese, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.584
NA - Nord America 1.906
AS - Asia 1.477
SA - Sud America 202
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 6.207
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.858
RU - Federazione Russa 1.049
GB - Regno Unito 645
CN - Cina 567
SG - Singapore 549
IT - Italia 184
SE - Svezia 180
BR - Brasile 161
IE - Irlanda 145
HK - Hong Kong 129
DE - Germania 121
FR - Francia 106
VN - Vietnam 101
FI - Finlandia 52
MX - Messico 23
PL - Polonia 23
CA - Canada 22
IN - India 22
AR - Argentina 19
NL - Olanda 18
JP - Giappone 17
KR - Corea 14
TR - Turchia 14
ID - Indonesia 13
UA - Ucraina 13
ZA - Sudafrica 13
BD - Bangladesh 11
ES - Italia 10
EC - Ecuador 9
BE - Belgio 8
AT - Austria 7
IQ - Iraq 7
LT - Lituania 7
MA - Marocco 6
AE - Emirati Arabi Uniti 5
PY - Paraguay 5
EU - Europa 4
VE - Venezuela 4
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
GR - Grecia 3
JO - Giordania 3
LK - Sri Lanka 3
PH - Filippine 3
CH - Svizzera 2
CL - Cile 2
EG - Egitto 2
HU - Ungheria 2
NP - Nepal 2
PK - Pakistan 2
SN - Senegal 2
TG - Togo 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BJ - Benin 1
CR - Costa Rica 1
DK - Danimarca 1
GT - Guatemala 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
MW - Malawi 1
MY - Malesia 1
NE - Niger 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SO - Somalia 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
YE - Yemen 1
Totale 6.207
Salva come PNG Salva come JPEG
Città #
Southend 609
Moscow 356
Chandler 300
Singapore 227
Ashburn 188
Dallas 171
Dublin 145
Beijing 144
Hong Kong 129
Woodbridge 105
Ann Arbor 74
Houston 60
The Dalles 59
Los Angeles 55
New York 51
Lawrence 46
Princeton 46
Jacksonville 44
Nanjing 42
Wilmington 38
Jinan 31
Ho Chi Minh City 28
Shenyang 26
São Paulo 24
Verona 23
Redondo Beach 20
Columbus 19
Hebei 19
Santa Clara 18
Munich 17
Buffalo 16
Changsha 15
Helsinki 15
Montreal 15
Brooklyn 14
Denver 14
Hanoi 14
Redwood City 14
Tianjin 14
Dong Ket 13
Haikou 13
Milan 13
Sindelfingen 13
Tokyo 13
Zhengzhou 13
Guangzhou 12
Johannesburg 10
Mexico City 10
Seoul 10
Stockholm 10
Taizhou 10
Warsaw 10
Jakarta 9
Jiaxing 9
Bologna 8
Brussels 8
Dearborn 8
London 8
Ningbo 8
Norwalk 8
Fuzhou 7
Kent 7
Nanchang 7
Seattle 7
Vienna 7
Ankara 6
Biên Hòa 6
Boston 6
Campinas 6
Chennai 6
Hangzhou 6
Lanzhou 6
Phoenix 6
Rome 6
Taiyuan 6
Turku 6
Chicago 5
Council Bluffs 5
Frankfurt am Main 5
Krakow 5
New Delhi 5
Orem 5
San Francisco 5
Amsterdam 4
Bussolengo 4
Catanzaro 4
Da Nang 4
Fairfield 4
Falkenstein 4
Groningen 4
Mumbai 4
Querétaro 4
Trento 4
Amman 3
Athens 3
Baku 3
Belo Horizonte 3
Betim 3
Brasília 3
Casablanca 3
Totale 3.658
Salva come PNG Salva come JPEG
Nome #
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 218
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 197
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 185
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 185
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 171
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 168
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 166
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 165
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 161
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 160
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 155
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 154
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 151
The development of PARP as a successful target for cancer therapy 151
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 151
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 149
AR-V7 and prostate cancer: The watershed for treatment selection? 148
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research 147
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 146
The route to personalized medicine in bladder cancer: where do we stand? 142
2015 and human cancer: back to overall survival 141
Inside the 2015 ASCO Genitourinary Cancers Symposium 134
Metabolic phenotype of bladder cancer 131
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 130
Metabolic alterations in renal cell carcinoma 129
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 129
Metabolic Alterations in Renal and Prostate Cancer 128
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 127
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer 124
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 123
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer 122
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 121
Acquired hemophagocytic syndrome: comment to the case report 119
Bladder cancer: molecular determinants of personalized therapy 118
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma 117
Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR? 112
Emerging Immunotargets in Bladder Cancer 109
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 108
Kidney cancer and 2014: is innovation really over? 107
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis 104
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 94
Role of STAT3 pathway in genitourinary tumors 89
Tp53 and its potential therapeutic role as a target in bladder cancer 83
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 80
The prospect of precision therapy for renal cell carcinoma 72
Present and future of personalized medicine in adult genitourinary tumors 63
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer 60
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 44
Totale 6.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.735
article - articoli 21.735
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.470
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 17 11 3 2 7 20 25
2021/2022282 15 66 2 32 23 8 3 21 10 8 11 83
2022/2023827 54 96 72 136 59 221 2 62 93 11 17 4
2023/2024357 13 34 25 32 75 36 10 39 5 18 60 10
2024/20251.019 48 54 51 234 27 37 23 20 199 47 87 192
2025/20262.227 220 162 212 707 898 28 0 0 0 0 0 0
Totale 6.288